Progressive myoclonic epilepsy as an adult-onset manifestation of Leigh syndrome due to m.14487T>C

医学 强直性脊柱炎 末端炎 妥珠单抗 内科学 百时美 物理疗法 阿达木单抗 胃肠病学 外科 关节炎 疾病 银屑病性关节炎
作者
Bart Dermaut,Sara Seneca,Lina Dom,Kaat Smets,Luc Ceulemans,Joél Smet,Boél De Paepe,Simon Tousseyn,Sarah Weckhuysen,Marc Gewillig,P. Pals,Paul M. Parizel,Jan De Bleecker,Paul Boon,Linda De Meırleır,Peter De Jonghe,Rudy Van Coster,Wim Van Paesschen,Patrick Santens
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:81 (1): 90-93 被引量:33
标识
DOI:10.1136/jnnp.2008.157354
摘要

Background

Axial spondyloarthritis (axSpA) is characterized by inflammation of the spine. However, the disease can also be associated with extra-spinal manifestations such as inflammation of the entheses (enthesitis) and peripheral joints, which can add to the burden of disease. RAPID-axSpA (NCT01087762) is a Phase 3 clinical trial of certolizumab pegol (CZP) in patients (pts) with axSpA including pts with (ankylosing spondylitis [AS]) or without (non-radiographic axSpA [nr-axSpA]) radiographic damage of the sacroiliac joints.1

Objectives

To report the impact of CZP treatment on enthesitis (measured by Maastricht Ankylosing Spondylitis Enthesitis Score [MASES]) and peripheral joint swelling and tenderness.

Methods

The RAPID-axSpA trial was double-blind and placebo (PBO)-controlled to Week (Wk) 24. Pts fulfilled ASAS criteria and had active axSpA. Pts were originally randomized 1:1:1 to either CZP 200mg Q2W, 400mg Q4W (following 400mg loading dose at Wks 0, 2, 4) or PBO. Enthesitis (MASES; count of 0–13 affected sites), swollen joints (SJC; 0–66 joints) and tender joints (TJC; 0–68 joints) were assessed at baseline and at each study visit to Wk24. Data are presented here for the subsets of pts within the Full Analysis Set (FAS) with ≥1 swollen joint, ≥1 tender joint or ≥1 enthesial site affected at baseline. LOCF imputation was used for pts escaping to CZP, withdrawing or having missing measurements. No analyses of statistical significance were carried out on these data.

Results

At baseline, of the 324 pts in the FAS, 229 had enthesitis in ≥1 enthesial site, with a mean MASES score of 5.1; 123 had ≥1 swollen joint, with a mean SJC of 4.2; and 212 had ≥1 tender joint, with a mean TJC of 6.6. Improvements were seen in all three extra-spinal measures following CZP treatment. At Wk24 the mean change from baseline in MASES for CZP-treated pts was -2.9 compared to -0.9 for PBO pts; for SJC the mean change from baseline for CZP pts was -2.8 compared to -0.7 for PBO pts; and for TJC the mean change from baseline for CZP pts was -2.7 compared to -0.4 in PBO pts. Baseline severity of extra-spinal manifestations and improvements observed to Wk24 were similar between the AS and nr-axSpA subpopulations (Table). Improvements were also similar between both CZP dosing regimens (data not shown).

Conclusions

CZP treatment of axSpA patients was associated with a marked improvement in measures of enthesitis and extra-spinal joint inflammation. Similar improvements were seen in both the AS and nr-axSpA subpopulations.

References

Landewé R. Ann Rheum Dis 2014;73:39-47

Acknowledgements

The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma.

Disclosure of Interest

P. Mease Grant/research support: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex, Consultant for: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex, Speakers bureau: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Crescendo, Genentech, Janssen, Lilly, Pfizer, UCB Pharma, M. Dougados Grant/research support: UCB Pharma, Abbvie, Pfizer, Lilly, Novartis, Consultant for: UCB Pharma, Abbvie, Pfizer, Lilly, Novartis, O. Davies Shareholder of: UCB Pharma, Employee of: UCB Pharma, T. Nurminen Employee of: UCB Pharma, J. Sieper Consultant for: Abbott, Merck, Pfizer, UCB Pharma, Novartis, Lilly, Janssen, Speakers bureau: Abbott, Merck, Pfizer, UCB Pharma, Novartis, Lilly, Janssen

DOI

10.1136/annrheumdis-2014-eular.1558
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
抹不掉的记忆完成签到,获得积分10
1秒前
1秒前
余杭村王小虎完成签到,获得积分10
2秒前
韭黄完成签到,获得积分20
6秒前
jeffrey完成签到,获得积分10
6秒前
Rondab应助机灵枕头采纳,获得10
12秒前
佳无夜完成签到,获得积分10
17秒前
摆哥完成签到,获得积分10
21秒前
66完成签到,获得积分10
26秒前
zlqq完成签到 ,获得积分10
26秒前
Hardskills发布了新的文献求助10
29秒前
30秒前
之_ZH完成签到 ,获得积分10
38秒前
gds2021完成签到 ,获得积分10
40秒前
你好呀嘻嘻完成签到 ,获得积分10
40秒前
梅特卡夫完成签到,获得积分10
42秒前
熊雅完成签到,获得积分10
43秒前
45秒前
睡到自然醒完成签到 ,获得积分10
46秒前
cis2014完成签到,获得积分10
48秒前
独特的大有完成签到 ,获得积分10
48秒前
量子星尘发布了新的文献求助10
49秒前
51秒前
xingyi完成签到,获得积分10
53秒前
54秒前
舒心的秋荷完成签到 ,获得积分10
57秒前
zz123发布了新的文献求助10
58秒前
liaomr完成签到 ,获得积分10
58秒前
粗犷的灵松完成签到,获得积分10
59秒前
吃小孩的妖怪完成签到 ,获得积分10
59秒前
ncuwzq完成签到,获得积分10
1分钟前
yshj完成签到 ,获得积分10
1分钟前
1分钟前
净禅完成签到 ,获得积分10
1分钟前
1分钟前
迷人的寒风完成签到,获得积分10
1分钟前
1分钟前
water应助科研通管家采纳,获得10
1分钟前
Lucas应助HHHAN采纳,获得10
1分钟前
无情修杰完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022